Risk reduction strategies like a bilateral prophylactic mastectomy, bilateral salpingo-oophorectomy, and tamoxifen is done in which conditions?
Reading File
These risk reduction strategies are primarily used in individuals with hereditary breast and ovarian cancer syndromes, particularly BRCA1/BRCA2 mutation carriers. Let me pull the detailed textbook content.
Searching sources...
Finding Sources
Finding Sources
Finding Sources
Good results. Let me now read the most relevant textbook sections for detailed content.
Reading File
Reading File
Reading File
Let me get a bit more detail on the specific indications and hereditary syndromes involved.
Reading File
Finding Sources
Reading File
Finding Sources
I now have comprehensive information from multiple authoritative textbooks. Here is a detailed, well-structured answer:
Risk Reduction Strategies: Bilateral Prophylactic Mastectomy, Bilateral Salpingo-Oophorectomy, and Tamoxifen
These interventions are offered to individuals at significantly elevated (high) risk of breast and/or ovarian cancer - primarily those with hereditary cancer predispositions. They are not offered to the general population.
1. Bilateral Prophylactic Mastectomy (BPM)
Primary indications:
| Condition | Risk Level |
|---|---|
| BRCA1 or BRCA2 mutation carriers | Very high (~70-85% lifetime breast cancer risk) |
| PALB2, PTEN, ATM, CHEK2 mutation carriers | High (data less robust, individualized decision) |
| Li-Fraumeni syndrome (TP53 mutation) | High lifetime risk |
| Cowden syndrome (PTEN mutation) | High lifetime risk |
| Strong family history (multiple first-degree relatives with breast cancer) without identified mutation | Moderate-to-high risk |
| Lobular carcinoma in situ (LCIS) | Increased risk marker |
| Contralateral prophylactic mastectomy in a newly diagnosed breast cancer patient with BRCA mutation | Risk of second primary cancer |
Efficacy:
- Reduces breast cancer risk by 90% in high-risk women (Hartmann et al., 1999).
- A meta-analysis of 2,555 BRCA1/2 carriers showed an 89% risk reduction with BPM.
- No statistically significant improvement in all-cause mortality with BPM alone, unlike prophylactic bilateral salpingo-oophorectomy (PBSO).
(Sabiston Textbook of Surgery, p. 2148-2152)
Contraindications to contralateral prophylactic mastectomy (CPM):
- Average-risk women with unilateral sporadic breast cancer
- Advanced primary cancer (T4, N3, or stage IV)
- High postoperative complication risk
- BRCA-negative patients in BRCA-positive families
- Males with breast cancer
2. Bilateral Salpingo-Oophorectomy (BSO / Risk-Reducing Salpingo-Oophorectomy, RRSO)
Primary indications:
| Condition | Details |
|---|---|
| BRCA1 mutation carriers | ~40-46% lifetime ovarian cancer risk; BSO recommended at age 35-40, or after childbearing is complete |
| BRCA2 mutation carriers | ~10-27% lifetime ovarian cancer risk; BSO recommended at age 40-45 |
| PALB2, RAD51C, RAD51D, BRIP1 mutation carriers | Elevated ovarian cancer risk; individualized recommendation |
| Lynch syndrome (MLH1, MSH2, MSH6, PMS2 mutations) | Elevated ovarian + endometrial cancer risk; BSO often recommended after childbearing |
| Creasy & Resnik: RRBSO | Recommended at age 35 or completion of childbearing in BRCA carriers |
Efficacy:
- 36% relative risk reduction in ovarian/primary peritoneal cancer incidence in BRCA mutation carriers (Harrison's Principles of Internal Medicine 22E).
- Additionally reduces breast cancer risk by ~45-50% (relative risk ~0.50) in BRCA carriers, especially when done before age 45-50.
- A meta-analysis in 7,323 BRCA1/2 carriers showed prophylactic BSO reduces breast cancer risk by 45% (Sabiston Textbook of Surgery).
Important caveat: Even after BSO, peritoneal carcinomas can still occur in 2-3% of women, as the entire peritoneum carries risk. There is also an increased risk of cardiovascular disease when BSO is done in premenopausal women.
(Harrison's Principles of Internal Medicine 22E, p. 192-194; Sabiston Textbook of Surgery, p. 2150)
3. Tamoxifen (Chemoprevention / Risk Reduction)
Tamoxifen is a selective estrogen receptor modulator (SERM) approved by the FDA for breast cancer risk reduction.
Indications (who qualifies):
| Criterion | Details |
|---|---|
| 5-year Gail model risk ≥1.66-1.7% (Gail relative risk ≥1.66%) | Women age 35-59 years |
| Women aged ≥60 years | All such women qualify, regardless of Gail score |
| Lobular carcinoma in situ (LCIS) | Tamoxifen gives a 59% risk reduction in this group |
| Atypical ductal hyperplasia (ADH) or atypical lobular hyperplasia (ALH) | 75% risk reduction with tamoxifen |
| DCIS post-mastectomy | Reduces risk of invasive disease |
| BRCA1/2 mutation carriers | May be used as an option, though surgical prevention is usually favored |
Key trials:
- NSABP P-1 trial (13,388 women): Tamoxifen 20 mg/day x 5 years reduced invasive breast cancer incidence by 49% (risk reduction only for ER-positive cancers).
- IBIS-I trial: 32% reduction in breast cancer incidence.
- STAR trial (NSABP P-2): Raloxifene was nearly equivalent to tamoxifen, but with a more favorable toxicity profile (45% less endometrial cancer, 25% fewer thromboembolic events).
Side effects that limit use:
- Endometrial cancer (2.5x higher risk, postmenopausal women)
- Deep vein thrombosis (1.6x higher)
- Pulmonary embolism (3.0x higher)
- Cataracts / cataract surgery (nearly 2x more frequent)
- Vasomotor symptoms (hot flashes)
Note: A reduced-dose option of tamoxifen 5 mg/day x 3 years is available for those who are symptomatic or cannot tolerate the standard dose.
(Sabiston Textbook of Surgery, p. 2103-2143; Schwartz's Principles of Surgery, p. 89-97)
Summary Table
| Intervention | Primary Conditions |
|---|---|
| Bilateral prophylactic mastectomy | BRCA1/2 mutations, PALB2/PTEN/ATM/CHEK2 mutations, Li-Fraumeni, Cowden syndrome, strong family history, LCIS |
| Bilateral salpingo-oophorectomy | BRCA1/2 mutations (primary), Lynch syndrome, PALB2/RAD51C/RAD51D/BRIP1 mutations |
| Tamoxifen | Gail risk ≥1.66% (age 35-59), age ≥60, LCIS, ADH, ALH, DCIS post-mastectomy |
The common thread across all three is elevated heritable or histologic risk, with BRCA1/BRCA2 mutations being the most compelling indication for surgical risk reduction, while tamoxifen targets a broader population of women with modestly elevated breast cancer risk.
This is a shared conversation. Sign in to Orris to start your own chat.